Cargando…
Mortality in the Melbourne injecting drug user cohort study (MIX)
BACKGROUND: There are few studies of mortality amongst people who inject drugs (PWID) in Australia. In this study, we estimate mortality in a cohort of PWID in Melbourne and examine predictors of mortality including health service use, demographic characteristics, drug use and personal wellbeing. FI...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674911/ https://www.ncbi.nlm.nih.gov/pubmed/26654430 http://dx.doi.org/10.1186/s12954-015-0089-3 |
_version_ | 1782404973011664896 |
---|---|
author | Nambiar, Dhanya Agius, Paul A. Stoové, Mark Hickman, Matthew Dietze, Paul |
author_facet | Nambiar, Dhanya Agius, Paul A. Stoové, Mark Hickman, Matthew Dietze, Paul |
author_sort | Nambiar, Dhanya |
collection | PubMed |
description | BACKGROUND: There are few studies of mortality amongst people who inject drugs (PWID) in Australia. In this study, we estimate mortality in a cohort of PWID in Melbourne and examine predictors of mortality including health service use, demographic characteristics, drug use and personal wellbeing. FINDINGS: We linked identifiers from the Melbourne injecting drug use cohort study (MIX; n = 655) to the National Death Index from 2008 to 2012 to estimate standardised mortality ratios (SMRs). Cox regression was used to examine the bivariate relationship between exposures determined at baseline and subsequent mortality. There were 24 (3.6 %) deaths over the study period. The mortality rate in the cohort was 1.0 per 100 PY (95 % CI 0.71–1.57), with an SMR of 17.3 (95 % CI 11.6–25.8). Baseline reports of four or more lifetime incarcerations (HR 3.65, 95 % CI 1.16–11.52), past month ambulance attendance (HR 4.43, 95 % CI 1.76–11.17), past month emergency department presentation (HR 3.44, 95 % CI 1.47–8.03) and past 6-month self-reported heroin overdose (HR 3.14, 95 % CI 1.24–7.96) were associated with increased mortality risk. CONCLUSIONS: Contact with emergency services, particularly for drug overdose, remains a lost opportunity to provide referrals for harm reduction and naloxone training programmes to PWID at greater risk of mortality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12954-015-0089-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4674911 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46749112015-12-11 Mortality in the Melbourne injecting drug user cohort study (MIX) Nambiar, Dhanya Agius, Paul A. Stoové, Mark Hickman, Matthew Dietze, Paul Harm Reduct J Brief Report BACKGROUND: There are few studies of mortality amongst people who inject drugs (PWID) in Australia. In this study, we estimate mortality in a cohort of PWID in Melbourne and examine predictors of mortality including health service use, demographic characteristics, drug use and personal wellbeing. FINDINGS: We linked identifiers from the Melbourne injecting drug use cohort study (MIX; n = 655) to the National Death Index from 2008 to 2012 to estimate standardised mortality ratios (SMRs). Cox regression was used to examine the bivariate relationship between exposures determined at baseline and subsequent mortality. There were 24 (3.6 %) deaths over the study period. The mortality rate in the cohort was 1.0 per 100 PY (95 % CI 0.71–1.57), with an SMR of 17.3 (95 % CI 11.6–25.8). Baseline reports of four or more lifetime incarcerations (HR 3.65, 95 % CI 1.16–11.52), past month ambulance attendance (HR 4.43, 95 % CI 1.76–11.17), past month emergency department presentation (HR 3.44, 95 % CI 1.47–8.03) and past 6-month self-reported heroin overdose (HR 3.14, 95 % CI 1.24–7.96) were associated with increased mortality risk. CONCLUSIONS: Contact with emergency services, particularly for drug overdose, remains a lost opportunity to provide referrals for harm reduction and naloxone training programmes to PWID at greater risk of mortality. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12954-015-0089-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-09 /pmc/articles/PMC4674911/ /pubmed/26654430 http://dx.doi.org/10.1186/s12954-015-0089-3 Text en © Nambiar et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Brief Report Nambiar, Dhanya Agius, Paul A. Stoové, Mark Hickman, Matthew Dietze, Paul Mortality in the Melbourne injecting drug user cohort study (MIX) |
title | Mortality in the Melbourne injecting drug user cohort study (MIX) |
title_full | Mortality in the Melbourne injecting drug user cohort study (MIX) |
title_fullStr | Mortality in the Melbourne injecting drug user cohort study (MIX) |
title_full_unstemmed | Mortality in the Melbourne injecting drug user cohort study (MIX) |
title_short | Mortality in the Melbourne injecting drug user cohort study (MIX) |
title_sort | mortality in the melbourne injecting drug user cohort study (mix) |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674911/ https://www.ncbi.nlm.nih.gov/pubmed/26654430 http://dx.doi.org/10.1186/s12954-015-0089-3 |
work_keys_str_mv | AT nambiardhanya mortalityinthemelbourneinjectingdrugusercohortstudymix AT agiuspaula mortalityinthemelbourneinjectingdrugusercohortstudymix AT stoovemark mortalityinthemelbourneinjectingdrugusercohortstudymix AT hickmanmatthew mortalityinthemelbourneinjectingdrugusercohortstudymix AT dietzepaul mortalityinthemelbourneinjectingdrugusercohortstudymix |